<DOC>
	<DOC>NCT00906685</DOC>
	<brief_summary>Central retinal vein occlusion is a leading cause of severe visual impairment. Until now, no treatment has been available to improve visual acuity. The present study intends to investigate if intravitreal bevacizumab can improve visual acuity as compared to sham-treated control patients.</brief_summary>
	<brief_title>Bevacizumab for Central Retinal Vein Occlusion Study</brief_title>
	<detailed_description />
	<mesh_term>Retinal Vein Occlusion</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>CRVO with duration &lt; 6 months Visual acuity of 20/800 to 20/50 CRVO with duration of &gt; 6 months previous treatment with antiangiogenic drugs</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>CRVO</keyword>
	<keyword>anti-VEGF</keyword>
	<keyword>Macular edema</keyword>
</DOC>